Literature DB >> 20378496

Chemotherapy resistance and retreatment: a dogma revisited.

Aung Naing1, Razelle Kurzrock.   

Abstract

The prevailing belief in cancer therapy is that retreatment with a given drug after the emergence of resistance is ineffective. Herein, we report several cases in which retreatment with drugs that had failed earlier in the disease trajectory caused renewed tumor regression. The possible biologic underpinnings that might explain this phenomenon are discussed.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20378496     DOI： 10.3816/CCC.2010.n.026

Source DB:  PubMed          Journal:  Clin Colorectal Cancer        ISSN： 1533-0028            Impact factor:   4.481


  12 in total

Review 1.  Drug rechallenge and treatment beyond progression--implications for drug resistance.

Authors:  Elizabeth A Kuczynski; Daniel J Sargent; Axel Grothey; Robert S Kerbel
Journal:  Nat Rev Clin Oncol       Date:  2013-09-03       Impact factor: 66.675

2.  A case of heavily pretreated rectal cancer with disseminated intravascular coagulation that improved following reintroduction of FOLFOX plus bevacizumab.

Authors:  Ayako Mizota; Kohei Shitara; Chihiro Kondo; Motoo Nomura; Tomoya Yokota; Daisuke Takahari; Takashi Ura; Kei Muro
Journal:  Int J Clin Oncol       Date:  2011-05-12       Impact factor: 3.402

Review 3.  Hepatocellular carcinoma: Where there is unmet need.

Authors:  Manojkumar Bupathi; Ahmed Kaseb; Funda Meric-Bernstam; Aung Naing
Journal:  Mol Oncol       Date:  2015-06-25       Impact factor: 6.603

4.  Ewing's sarcoma: overcoming the therapeutic plateau.

Authors:  Vivek Subbiah; Razelle Kurzrock
Journal:  Discov Med       Date:  2012-06       Impact factor: 2.970

5.  Targeted morphoproteomic profiling of Ewing's sarcoma treated with insulin-like growth factor 1 receptor (IGF1R) inhibitors: response/resistance signatures.

Authors:  Vivek Subbiah; Aung Naing; Robert E Brown; Helen Chen; Laurence Doyle; Patricia LoRusso; Robert Benjamin; Pete Anderson; Razelle Kurzrock
Journal:  PLoS One       Date:  2011-04-06       Impact factor: 3.240

6.  Multiple gene aberrations and breast cancer: lessons from super-responders.

Authors:  Jennifer J Wheler; Johnique T Atkins; Filip Janku; Stacy L Moulder; Roman Yelensky; Philip J Stephens; Razelle Kurzrock
Journal:  BMC Cancer       Date:  2015-05-29       Impact factor: 4.430

7.  Novel secondary somatic mutations in Ewing's sarcoma and desmoplastic small round cell tumors.

Authors:  Yunyun Jiang; Vivek Subbiah; Filip Janku; Joseph A Ludwig; Aung Naing; Robert S Benjamin; Robert E Brown; Pete Anderson; Razelle Kurzrock
Journal:  PLoS One       Date:  2014-08-13       Impact factor: 3.240

8.  Exploring response signals and targets in aggressive unresectable hepatocellular carcinoma: an analysis of targeted therapy phase 1 trials.

Authors:  Ishwaria M Subbiah; Gerald S Falchook; Ahmed O Kaseb; Kenneth R Hess; Apostolia M Tsimberidou; Siqing Fu; Vivek Subbiah; David S Hong; Aung Naing; Sarina A Piha-Paul; Owais Akmal; Filip Janku; Razelle Kurzrock
Journal:  Oncotarget       Date:  2015-09-29

9.  Targeting the apoptotic pathway in chondrosarcoma using recombinant human Apo2L/TRAIL (dulanermin), a dual proapoptotic receptor (DR4/DR5) agonist.

Authors:  Vivek Subbiah; Robert E Brown; Jamie Buryanek; Jonathan Trent; Avi Ashkenazi; Roy Herbst; Razelle Kurzrock
Journal:  Mol Cancer Ther       Date:  2012-08-20       Impact factor: 6.009

10.  Rechallenge of oxaliplatin-containing regimens in the third- or later-line therapy for patients with heavily treated metastatic colorectal cancer.

Authors:  Qiong Yang; Yuanyuan Huang; Zhimin Jiang; Huizhong Wang; Weiyu Li; Bei Zhang; Derong Xie
Journal:  Onco Targets Ther       Date:  2018-05-01       Impact factor: 4.147
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.